{"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.4","value":"62.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"0=Fully active"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"1=Restricted in physically strenuous activity"}],"paramType":"NUMBER","title":"Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Obatoclax mesylate IV 14 mg/m^2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Obatoclax mesylate IV 30 mg/m^2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Obatoclax mesylate IV 40 mg/m^2"}],"paramType":"NUMBER","title":"Dose Level","unitOfMeasure":"participants"}],"populationDescription":"One patient withdrew prior to beginning treatment and was replaced, thus, will be excluded in all analysis."}